Alpha 1-antitrypsin deficiency laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 41: Line 41:
**[[Albumins|Albumin]]
**[[Albumins|Albumin]]
**[[Clotting|Routine clotting function]]
**[[Clotting|Routine clotting function]]
**([[Activated partial thromboplastin time]]
**[[Activated partial thromboplastin time]]
**[[International normalized ratio|International normalized ratio)]].
**[[International normalized ratio|International normalized ratio]].


==References==
==References==

Revision as of 17:52, 9 January 2018

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency laboratory findings

CDC on Alpha 1-antitrypsin deficiency laboratory findings

Alpha 1-antitrypsin deficiency laboratory findings in the news

Blogs on Alpha 1-antitrypsin deficiency laboratory findings

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

A reduced concentration of serum alpha1-antitrypsin level is diagnostic of AATD. Laboratory findings consistent with the diagnosis of AATD include moderate-to-severe airflow obstruction with an FEV1 in the range of 30-40% of the predicted value, reduced vital capacity, increased lung volumes secondary to air trapping (residual volume >120% of predicted value) are usually present, diffusing capacity values are reduced substantially (<50% of predicted value) in most symptomatic patients. Serum alpha1-antitrypsin levels are determined by nephelometry. Serum testing is used for diagnostic testing in those patients with family histories compatible with the alpha1-antitrypsin deficiency or with siblings with known alpha1-antitrypsin deficiency. In patients with clinical features that are highly suggestive of alpha1-antitrypsin deficiency but whose serum levels are within the reference range the next best step is to perform a functional assay of alpha1 antiprotease, which measures the ability of the patient's serum to inhibit human leukocyte elastase. Perform liver function tests in patients with low or borderline levels of alpha1-antitrypsin. Measurement of serum transaminases, bilirubin, albumin, and routine clotting function (activated partial thromboplastin time and international normalized ratio).

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of AATD include :
    • Moderate-to-severe airflow obstruction with an FEV1 in the range of 30-40% of the predicted value
    • Reduced vital capacity
    • Increased lung volumes secondary to air trapping (residual volume >120% of predicted value) are usually present
    • Diffusing capacity values are reduced substantially (<50% of predicted value) in most symptomatic patients
  • AATD testing should be considered as a laboratory diagnosis and not as a clinical diagnosis.

Serum alpha1-antitrypsin levels

Serum alpha1-antitrypsin levels are determined by nephelometry.

Serum testing is used for diagnostic testing in those patients with family histories compatible with alpha1-antitrypsin deficiency or with siblings with known alpha1-antitrypsin deficiency.

ATS/ERS AAT Deficiency Task Force does not recommend fetal testing or population screening unless:

  • Prevalence of AATD is high (>1 case per 1500 population)
  • Smoking is prevalent
  • Adequate counseling services are available

Serum alpha1-antitrypsin levels has a normal reference range of 100-300 mg/dL. Levels less than 80 mg/dL suggest a significant risk for lung disease. Serum alpha1-antitrypsin level alone has a low sensitivity for detecting AATD.

Emphysema is common below 11 mmol/L (80 mg/mL) which represents the threshold level.

Functional assay of alpha1-antiprotease

  • In patients with clinical features that are highly suggestive of alpha1-antitrypsin deficiency but whose serum levels are within the reference range the next best step is to perform functional assay of alpha1 antiprotease, which measures the ability of the patient's serum to inhibit human leukocyte elastase.
  • Perform liver function tests in patients with low or borderline levels of alpha1-antitrypsin.

References

  1. Parr DG, Sevenoaks M, Deng C, Stoel BC, Stockley RA (2008). "Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances". Respir. Res. 9: 21. doi:10.1186/1465-9921-9-21. PMC 2287169. PMID 18271964.
  2. Greene DN, Elliott-Jelf MC, Straseski JA, Grenache DG (2013). "Facilitating the laboratory diagnosis of α1-antitrypsin deficiency". Am. J. Clin. Pathol. 139 (2): 184–91. doi:10.1309/AJCP6XBK8ULZXWFP. PMID 23355203.


Template:WikiDoc Sources